Study shows Oxford Covid vaccine has less protection against South African variant

Researchers say vaccines' focus must shift to protecting people from hospitalisation and death

• Coronavirus - latest updates
• See all our coronavirus coverage

The Oxford/AstraZeneca vaccine will not stop people becoming ill if they contract the South African variant of Covid-19, researchers have confirmed, warning that vaccines' focus needs to shift from population immunity to protecting individuals from hospitalisation and death.

The small study in 2,000 people aged 31, who are less likely to become severely ill, adds to evidence from big trials of other vaccines carried out after the variant appeared in South Africa. Trial data from the Janssen and Novavax vaccines showed efficacy in South Africa was up to 60% against the variant, substantially lower than against the original virus.